Böse Zungen behaupten ...
| eröffnet am: | 05.05.03 13:00 von: | mario huana |
| neuester Beitrag: | 07.05.09 16:47 von: | Waleshark |
| Anzahl Beiträge: | 8 | |
| Leser gesamt: | 9096 | |
| davon Heute: | 4 | |
bewertet mit 1 Stern |
||
|
|
||
05.05.03 13:00
#1
mario huana
Böse Zungen behaupten ...
... TITAN PHARMACEUTICALS (WKN: 914404 oder ISIN: US8883141017)wäre eine Investion wert. Kennt jemand diesen Wert bzw. kann jemand das Portfolio realistisch einschätzen?!
Was ich jedenfalls interessant finde sind die strategischen Partnerschaften mit Schering und Novartis.
Titan Pharmaceuticals, Inc. (TTP) is a biopharmaceutical company developing proprietary therapeutics for the treatment of central nervous system disorders, cancer, and other serious and life threatening diseases. As of June 30, 2002, the company has ten products in development, seven of which are in clinical development, with two products in expanded human trials for safety and efficacy, known as Phase III clinical trials. TTP has five products in earlier stage trials for dosing, and preliminary safety and efficacy, known as Phase I and Phase II clinical trials. In addition to these programs, it has three products in pre-clinical development. TTP conducts a small portion of its operations through two subsidiaries: 81%-owned Ingenex, Inc. and 79%-owned ProNeura, Inc. Ingenex is engaged in the development of gene-based therapeutics for the treatment of cancer. ProNeura develops cost effective, long-term treatment solutions to neurologic and psychiatric disorders through an implantable drug delivery system. TTP is independently developing its product candidates and also utilizing strategic partnerships, including collaborations with Novartis Pharma AG and Schering AG, as well as collaborations with several government-sponsored clinical cooperative groups. These collaborations help fund product development and enable the company to retain significant economic interest in its products. The company's lead CNS therapeutic product candidate, iloperidone, is being developed for the treatment of schizophrenia, the most common form of psychosis. As of Dec. 31, 2001, Iloperidone is being evaluated in an extensive Phase III program administered by Novartis comprising over 3,500 patients at more than 200 sites in 24 countries. TTP's products are at various stages of development and may not be successfully developed or commercialized. The company does not have any products being sold on the commercial market. Its proposed products will require significant further capital expenditures, development, testing, and regulatory clearances prior to commercialization. The company may experience unanticipated problems relating to product development and cannot predict whether it will successfully develop and commercialize any products.
Gruss Mario Huana
Was ich jedenfalls interessant finde sind die strategischen Partnerschaften mit Schering und Novartis.
Titan Pharmaceuticals, Inc. (TTP) is a biopharmaceutical company developing proprietary therapeutics for the treatment of central nervous system disorders, cancer, and other serious and life threatening diseases. As of June 30, 2002, the company has ten products in development, seven of which are in clinical development, with two products in expanded human trials for safety and efficacy, known as Phase III clinical trials. TTP has five products in earlier stage trials for dosing, and preliminary safety and efficacy, known as Phase I and Phase II clinical trials. In addition to these programs, it has three products in pre-clinical development. TTP conducts a small portion of its operations through two subsidiaries: 81%-owned Ingenex, Inc. and 79%-owned ProNeura, Inc. Ingenex is engaged in the development of gene-based therapeutics for the treatment of cancer. ProNeura develops cost effective, long-term treatment solutions to neurologic and psychiatric disorders through an implantable drug delivery system. TTP is independently developing its product candidates and also utilizing strategic partnerships, including collaborations with Novartis Pharma AG and Schering AG, as well as collaborations with several government-sponsored clinical cooperative groups. These collaborations help fund product development and enable the company to retain significant economic interest in its products. The company's lead CNS therapeutic product candidate, iloperidone, is being developed for the treatment of schizophrenia, the most common form of psychosis. As of Dec. 31, 2001, Iloperidone is being evaluated in an extensive Phase III program administered by Novartis comprising over 3,500 patients at more than 200 sites in 24 countries. TTP's products are at various stages of development and may not be successfully developed or commercialized. The company does not have any products being sold on the commercial market. Its proposed products will require significant further capital expenditures, development, testing, and regulatory clearances prior to commercialization. The company may experience unanticipated problems relating to product development and cannot predict whether it will successfully develop and commercialize any products.
Gruss Mario Huana
13.12.06 19:16
#2
Stöffen
Positive Iloperidone Resultate in Phase III
Werde ich ebenso auf meine Watch-List setzen wie auch die weiter unten erwähnte Vanda Pharmaceuticals Co. ( A0JJT3 ), Kurse von Titan & Vanda gingen nach Bekanntgabe dieser Meldung durch die Decke, bröckeln z.Z. wieder etwas ab, heute - 5%.
Gruß + Stöffen
Titan Reports Positive Results in Iloperidone Phase III Clinical Trial
Titan Pharmaceuticals, Inc. (AMEX:TTP) today announced positive results from a Phase III clinical trial evaluating iloperidone, an atypical antipsychotic, in patients with schizophrenia. In this important study, iloperidone demonstrated statistically significant improvement compared to placebo on the Positive and Negative Symptom Scale (PANSS), the trial's primary endpoint. Iloperidone also achieved significant efficacy on the positive and negative symptom subscales of PANSS. The safety profile was consistent with what has been observed in previous iloperidone Phase III trials.
Iloperidone's efficacy and safety was also evaluated in this study in patients with specific genetic profiles using pharmacogenetics (PG), in order to potentially give physicians and patients information to help individualize their antipsychotic therapy. It had been previously identified that a certain polymorphism in a gene, occurring in approximately 70% of patients, may be associated with the pathogenesis of schizophrenia and appeared to correlate with iloperidone response. Iloperidone achieved statistical significance vs. placebo on the PANSS scale in these patients, with a magnitude of response greater than that seen in the overall iloperidone population.
The Phase III trial was a randomized, double-blind, placebo-controlled, multi-center, 4 week study that enrolled 604 patients with schizophrenia. The trial evaluated 12 mg of iloperidone dosed twice-daily, or 24 mg per day. The primary endpoint was efficacy vs. placebo in PANSS (total) using the Mixed Method Repeated Measures (MMRM) methodology. The secondary endpoint was efficacy in the previous described genetic subpopulation.
The efficacy results vs. placebo include:
* Efficacy (intent to treat population):
* PANSS (total): p=0.006
* PANSS (positive symptoms only): p=0.0009
* PANSS (negative symptoms only): p=0.027
* Brief Psychiatric Rating Scale (BPRS): p=0.0128
* Efficacy (genetic subpopulation):
* PANSS (total): p=0.002
Using Last Observation Carried Forward (LOCF) methodology, iloperidone achieved statistical significance in both the primary and secondary endpoints. Iloperidone efficacy was also equal to the active control arm.
The study also evaluated the effect of iloperidone on the QT interval, a well understood atypical antipsychotic class side effect. The mean QT prolongation was consistent with previous experience. No patients experienced QT intervals in excess of 500 milliseconds, a threshold of concern to the FDA. The study also confirmed, with an additional genetic marker, that the QT prolongation was shorter in the majority of patients who are good iloperidone metabolizers.
The specific results include:
* QTc change from baseline:
* All patients: 11.4 milliseconds (msec)
* Good metabolizers: 10.4 msec
* Poor metabolizers: 15.0 msec (p=0.008, good vs. poor)
"We are very pleased with these results for iloperidone in this Phase III study", stated Louis R. Bucalo, Chairman, President and CEO of Titan Pharmaceuticals. "These results strongly support our position in the advancement of iloperidone".
The Phase III study was performed by Vanda Pharmaceuticals Inc. (Nasdaq:VNDA). Vanda acquired the rights to iloperidone from Titan's sublicensee, Novartis. Vanda plans to file an NDA for iloperidone by the end of 2007. Titan's agreements provide that Titan will receive a royalty of between 8-10% on worldwide sales of iloperidone.
Gruß + Stöffen
Titan Reports Positive Results in Iloperidone Phase III Clinical Trial
Titan Pharmaceuticals, Inc. (AMEX:TTP) today announced positive results from a Phase III clinical trial evaluating iloperidone, an atypical antipsychotic, in patients with schizophrenia. In this important study, iloperidone demonstrated statistically significant improvement compared to placebo on the Positive and Negative Symptom Scale (PANSS), the trial's primary endpoint. Iloperidone also achieved significant efficacy on the positive and negative symptom subscales of PANSS. The safety profile was consistent with what has been observed in previous iloperidone Phase III trials.
Iloperidone's efficacy and safety was also evaluated in this study in patients with specific genetic profiles using pharmacogenetics (PG), in order to potentially give physicians and patients information to help individualize their antipsychotic therapy. It had been previously identified that a certain polymorphism in a gene, occurring in approximately 70% of patients, may be associated with the pathogenesis of schizophrenia and appeared to correlate with iloperidone response. Iloperidone achieved statistical significance vs. placebo on the PANSS scale in these patients, with a magnitude of response greater than that seen in the overall iloperidone population.
The Phase III trial was a randomized, double-blind, placebo-controlled, multi-center, 4 week study that enrolled 604 patients with schizophrenia. The trial evaluated 12 mg of iloperidone dosed twice-daily, or 24 mg per day. The primary endpoint was efficacy vs. placebo in PANSS (total) using the Mixed Method Repeated Measures (MMRM) methodology. The secondary endpoint was efficacy in the previous described genetic subpopulation.
The efficacy results vs. placebo include:
* Efficacy (intent to treat population):
* PANSS (total): p=0.006
* PANSS (positive symptoms only): p=0.0009
* PANSS (negative symptoms only): p=0.027
* Brief Psychiatric Rating Scale (BPRS): p=0.0128
* Efficacy (genetic subpopulation):
* PANSS (total): p=0.002
Using Last Observation Carried Forward (LOCF) methodology, iloperidone achieved statistical significance in both the primary and secondary endpoints. Iloperidone efficacy was also equal to the active control arm.
The study also evaluated the effect of iloperidone on the QT interval, a well understood atypical antipsychotic class side effect. The mean QT prolongation was consistent with previous experience. No patients experienced QT intervals in excess of 500 milliseconds, a threshold of concern to the FDA. The study also confirmed, with an additional genetic marker, that the QT prolongation was shorter in the majority of patients who are good iloperidone metabolizers.
The specific results include:
* QTc change from baseline:
* All patients: 11.4 milliseconds (msec)
* Good metabolizers: 10.4 msec
* Poor metabolizers: 15.0 msec (p=0.008, good vs. poor)
"We are very pleased with these results for iloperidone in this Phase III study", stated Louis R. Bucalo, Chairman, President and CEO of Titan Pharmaceuticals. "These results strongly support our position in the advancement of iloperidone".
The Phase III study was performed by Vanda Pharmaceuticals Inc. (Nasdaq:VNDA). Vanda acquired the rights to iloperidone from Titan's sublicensee, Novartis. Vanda plans to file an NDA for iloperidone by the end of 2007. Titan's agreements provide that Titan will receive a royalty of between 8-10% on worldwide sales of iloperidone.
07.05.09 12:46
#4
Benull
vielleicht das hier??
das ist das einzige was ich gefunden habe
http://www.tradingmarkets.com/.site/news/TOP%20STORY/2313482/
http://www.tradingmarkets.com/.site/news/TOP%20STORY/2313482/
07.05.09 12:56
#5
Goethe21
Wahnisnn...
so was sieht man nicht alle Tage...
hoffen wir das Bei GENTA etwas ähnliches passiert :):)
hoffen wir das Bei GENTA etwas ähnliches passiert :):)
07.05.09 15:59
#7
Mailo25
KAUF?
Lohnt sich noch die Aktie zu kaufen, denn die ist ja schon auf 0,70 gestiegen???
Liebe Grüße
07.05.09 16:47
#8
Waleshark
Mit der Aktie kann man schnell Millionär werden...
wenn man im Moment Milliardär ist. Wer hier investiert ist nicht zu helfen.
Grüße vom Waleshark.
Grüße vom Waleshark.